IVIG Treatment in CIDP with HOCM

IVIG Efficacy and Administration

Treatment with IVIG can lead to clinical improvement in patients with CIDP, with effects seen as early as 8 days after administration, and is typically given at monthly intervals to maintain remission, according to the British Journal of Dermatology guidelines 1
The American Heart Association recommends that patients with HOCM should be monitored closely during IVIG infusion for signs of hemodynamic compromise, as IVIG administration can increase intravascular volume and worsen LVOT obstruction 2

The American College of Cardiology recommends avoiding dopamine, dobutamine, norepinephrine, and other intravenous positive inotropic drugs in patients with obstructive HCM during treatment, due to potential harm 2
Pre-treatment cardiac assessment is recommended to evaluate baseline LVOT obstruction severity and hemodynamic status in patients with HOCM, according to the Circulation guidelines 2
Consider slower infusion rates (0.4 g/kg/day over 3-5 days) to minimize hemodynamic stress, as recommended by the Mayo Clinic Proceedings 3

The British Journal of Dermatology guidelines warn of potential adverse effects including headache, aseptic meningitis, and anaphylaxis, particularly in IgA-deficient patients 1
Volume overload, which may exacerbate LVOT obstruction in HOCM, is a potential adverse effect to monitor, according to the Circulation guidelines 2
Thromboembolic events, which may be of particular concern in patients with HOCM, are a potential adverse effect to monitor, as recommended by the Journal of the National Comprehensive Cancer Network 4